The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
-
BUSINESS Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President
January 30, 2025
-
REGULATORY Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment
January 30, 2025
-
REGULATORY MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
January 30, 2025
-
BUSINESS Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
-
REGULATORY LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
-
BUSINESS Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib
January 27, 2025
-
BUSINESS MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
-
REGULATORY MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
-
BUSINESS Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market
January 22, 2025
-
REGULATORY Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
-
BUSINESS Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
-
BUSINESS Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
-
REGULATORY 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums
January 16, 2025
-
REGULATORY Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister
January 15, 2025
-
BUSINESS SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
-
BUSINESS Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
-
COMMENTARY Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
-
ORGANIZATION Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
-
REGULATORY MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…